Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation

Blood

Volumn 100, Issue 1, 2002, Pages 17-21

  Angelucci, Emanuele ^a,b,c   Muretto, Pietro ^a,b   Nicolucci, Antonio ^a,b   Baronciani, Donatella ^a,b   Erer, Buket ^a,b   Gaziev, Javid ^a,b   Ripalti, Marta ^a,b   Sodani, Pietro ^a,b   Tomassoni, Silvia ^a,b   Visani, Giuseppe ^a,b   Lucarelli, Guido ^a,b  

^a SAN SALVATORE HOSPITAL   (Italy)

^b Santa Maria Imbaro ^*  (Italy)

^c Ospedale Oncologico A Businco   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BUSULFAN; CHELATING AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE;

ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CHELATION THERAPY; CHILD; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRON OVERLOAD; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THALASSEMIA MAJOR; VIRUS INFECTION;

EID: 0036660189     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.1.17     Document Type: Article

References (25)

1. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322:417-421.
2. Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: resuits in class 3 patients. Blood. 1996;87:2082-2088.
3. Angelucci E, Muretto P, Lucarelli G, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Blood. 1997;90:994-998.
4. Giardini C, Galimberti M, Lucarelli G, et al. Desferioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation. Br J Haematol. 1995;89:868-873.
5. Giardini C, Galimberti M, Lucarelli G, et al. Alfainterferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia. Bone Marrow Transplant. 1997;20:767-772.
6. Angelucci E, Baronciani D, Lucarelli G, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol. 1995;89:757-761.
7. Bravo AA, Sheth SG, Chopra S. Current concepts: liver biopsy. N Engl J Med. 2001;7:495-500.
8. Ishak KG, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
9. Olynyk JK, O'Neill R, Britton RS, Bacon BR. Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: diagnostic implications. Gastroenterology. 1994;106:674-677.
10. International Commission on Radiological Protection: Report of the Task Group on Reference Man: a report prepared by the task group of Committee 2 of the International Commission on Radiological Protection. Oxford, United Kingdom: Pergamon Press; 1975:144-148 (ICRP publication 23).
11. Angelucci E, Brittenham GM, McLaren C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343:327-331.
12. Olivieri NF, Brittenham GM, McLaren C, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417-423.
13. Mariotti E, Angelucci E, Agostini A, Baronciani D, Sgarbi E, Lucarelli G. Evaluation of cardiac status in iron-loaded thalassemia patients following bone marrow transplantation: improvement in cardiac function during reduction in iron burden. Br J Haematol. 1998;103:916-921.
14. Loreal O, Deugnier Y, Moirand R, et al. Liver fibrosis in genetic hemochromatosis: respective roles of iron and non-iron related factors in 127 homozygous patients. J Hepatol. 1992;16:122-127.
15. Kowdley KV, Kaplan MM. Iron-chelation therapy with oral deferiprone: toxicity or lack of efficacy? N Engl J Med. 1998;339:468-469.
16. Tricta F, Spino M. Iron chelation with oral deferiprone in patients with thalassemia [letter]. N Engl J Med. 1998;339:1710-1714.
17. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med. 1994;331:1607-1611.
18. MaKris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR. The natural history of chronic hepatitis C in haemiphiliacs. Br J Haematol. 1996;94:746-752.
19. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusual rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
20. Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood. 1999;93:3259-3266.
21. Andreani M, Centis F, Lucarelli G, et al. Immunologic recovery in thalassemic marrow graft recipients following high-dose busulfan and cyclophosphamide. Transplantation. 1988;46:394-398.
22. Paulin T, Ringden O, Nilsson B. Immunological recovery after bone marrow transplantation: role of age, graft-versus-host-disease, prednisolone treatment and infections. Bone Marrow Transplant. 1987;1:317-328.
23. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet. 1997;349:825-832.
24. Kenny-Walsh E, for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 1999;340:1228-1233.
25. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999;341:866-870.